Experimental CAR-T therapy for myeloma trial pulled before start

NCT ID NCT07196124

Terminated Disease control Sponsor: Guangzhou Bio-gene Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial aimed to test a new immune cell therapy called BCMA/GPRC5D CAR-T in people with relapsed or refractory multiple myeloma. The study was designed to check safety and dosing, but it was withdrawn before any patients were enrolled. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA/GPRC5D CAR-T (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat multiple myeloma.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results are available. CAR-T therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA REFRACTORY

More trials for these conditions

Other studies related to the condition(s) this trial covers.